Mednax Cost Of Revenue vs Non Operating Income Net Other Analysis
MD Stock | USD 8.22 0.05 0.61% |
Mednax financial indicator trend analysis is infinitely more than just investigating Mednax Inc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mednax Inc is a good investment. Please check the relationship between Mednax Cost Of Revenue and its Non Operating Income Net Other accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Cost Of Revenue vs Non Operating Income Net Other
Cost Of Revenue vs Non Operating Income Net Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mednax Inc Cost Of Revenue account and Non Operating Income Net Other. At this time, the significance of the direction appears to have very week relationship.
The correlation between Mednax's Cost Of Revenue and Non Operating Income Net Other is 0.25. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Mednax Inc, assuming nothing else is changed. The correlation between historical values of Mednax's Cost Of Revenue and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Mednax Inc are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Cost Of Revenue i.e., Mednax's Cost Of Revenue and Non Operating Income Net Other go up and down completely randomly.
Correlation Coefficient | 0.25 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Cost Of Revenue
Cost of Revenue is found on Mednax Inc income statement and represents the costs associated with goods and services Mednax provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Non Operating Income Net Other
Most indicators from Mednax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mednax Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At present, Mednax's Discontinued Operations is projected to decrease significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 6.9 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.11.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 513.2M | 467.0M | 421.6M | 542.2M | Total Revenue | 1.9B | 2.0B | 2.0B | 1.5B |
Mednax fundamental ratios Correlations
Click cells to compare fundamentals
Mednax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mednax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.1B | 3.3B | 2.7B | 2.3B | 2.2B | 2.2B | |
Short Long Term Debt Total | 1.8B | 1.8B | 1.1B | 753.6M | 701.6M | 521.4M | |
Other Current Liab | (23.4M) | (21.2M) | (22.2M) | 200.0M | 350.8M | 368.3M | |
Total Current Liabilities | 511.9M | 423.2M | 394.1M | 374.2M | 388.9M | 284.3M | |
Total Stockholder Equity | 1.5B | 747.7M | 896.7M | 891.6M | 849.1M | 1.2B | |
Property Plant And Equipment Net | 82.8M | 56.0M | 65.5M | 66.9M | 145.9M | 285.9M | |
Net Debt | 1.7B | 680.9M | 678.4M | 743.7M | 628.4M | 431.5M | |
Retained Earnings | 510.2M | (286.4M) | (155.4M) | (89.1M) | (149.5M) | (142.0M) | |
Accounts Payable | 511.9M | 423.2M | 394.1M | 31.9M | 34.6M | 32.9M | |
Cash | 112.8M | 1.1B | 387.4M | 9.8M | 73.3M | 89.9M | |
Non Current Assets Total | 3.5B | 1.8B | 2.0B | 2.0B | 1.7B | 1.9B | |
Non Currrent Assets Other | (162.4M) | 107.4M | (88.3M) | (105.9M) | 82.2M | 86.3M | |
Cash And Short Term Investments | 112.8M | 1.2B | 387.4M | 9.8M | 177.7M | 106.1M | |
Net Receivables | 498.9M | 241.9M | 301.8M | 296.8M | 279.9M | 228.1M | |
Common Stock Shares Outstanding | 83.5M | 83.4M | 85.8M | 84.1M | 82.2M | 77.1M | |
Liabilities And Stockholders Equity | 4.1B | 3.3B | 2.7B | 2.3B | 2.2B | 2.2B | |
Non Current Liabilities Total | 2.1B | 2.2B | 1.4B | 1.1B | 981.8M | 731.0M | |
Other Current Assets | 45.4M | 78.7M | 51.7M | 28.1M | 12.3M | 11.7M | |
Other Stockholder Equity | 987.9M | 1.0B | 1.0B | 983.6M | 999.9M | 695.6M | |
Total Liab | 2.6B | 2.6B | 1.8B | 1.5B | 1.4B | 982.2M | |
Property Plant And Equipment Gross | 177.3M | 132.2M | 70.2M | 73.3M | 288.6M | 303.1M | |
Total Current Assets | 657.0M | 1.5B | 740.8M | 334.8M | 483.5M | 382.4M | |
Accumulated Other Comprehensive Income | 78K | 3.5M | 1.3M | (3.7M) | (2.2M) | (2.3M) | |
Short Term Debt | 23.4M | 21.2M | 22.2M | 36.5M | 36.0M | 37.8M | |
Common Stock Total Equity | 842K | 856K | 864K | 829K | 953.4K | 643.9K | |
Common Stock | 842K | 856K | 864K | 829K | 840K | 655.1K | |
Other Liab | 330.2M | 372.4M | 365.9M | 348.7M | 401.0M | 421.0M | |
Other Assets | 1.8B | 217.8M | 219.4M | 229.1M | 263.5M | 212.4M | |
Intangible Assets | 274.4M | 26.6M | 21.6M | 18.5M | 21.2M | 20.2M | |
Property Plant Equipment | 129.1M | 76.2M | 70.2M | 73.3M | 84.3M | 64.4M | |
Long Term Debt | 1.7B | 1.7B | 1.0B | 636.4M | 611.6M | 643.8M | |
Good Will | 3.1B | 1.7B | 1.8B | 1.8B | 1.4B | 2.2B | |
Short Term Investments | 74.5M | 104.9M | 99.7M | 93.2M | 104.5M | 109.7M | |
Net Tangible Assets | (9.4M) | (757.1M) | 896.5M | 891.6M | 1.0B | 1.1B | |
Long Term Debt Total | 1.7B | 1.7B | 1.0B | 636.4M | 731.8M | 1.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Mednax Inc information on this page should be used as a complementary analysis to other Mednax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Mednax Stock analysis
When running Mednax's price analysis, check to measure Mednax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mednax is operating at the current time. Most of Mednax's value examination focuses on studying past and present price action to predict the probability of Mednax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mednax's price. Additionally, you may evaluate how the addition of Mednax to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Mednax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.71) | Earnings Share (0.12) | Revenue Per Share 24.244 | Quarterly Revenue Growth 0.008 | Return On Assets 0.0424 |
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.